-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PMW+5yaEYFSh76Pa+DXrqMq/mwIs+hd6ehyq7ufmhWTrf4hJh3/1HgCt48UNJpNd MQ7TemkkLhZzImXuS1Y9fg== 0001225208-10-013993.txt : 20100526 0001225208-10-013993.hdr.sgml : 20100526 20100526162353 ACCESSION NUMBER: 0001225208-10-013993 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100524 FILED AS OF DATE: 20100526 DATE AS OF CHANGE: 20100526 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GERAGHTY JAMES A CENTRAL INDEX KEY: 0001239746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 10859862 MAIL ADDRESS: STREET 1: GTC BIOTHERAPEUTICS, INC. STREET 2: 175 CROSSING BOULEVARD CITY: FRAMINGHAM STATE: MA ZIP: 01702 4 1 doc4.xml X0303 4 2010-05-24 0000732485 GENZYME CORP GENZ 0001239746 GERAGHTY JAMES A 500 KENDALL STREET CAMBRIDGE MA 02142 1 Senior Vice President Genzyme common stock (GENZ) 2010-05-24 4 M 0 5000 0 A 7685 D Genzyme common stock (GENZ) 2010-05-25 4 S 0 2329 45.59 D 5356 D Genzyme common stock (GENZ) 112 I By 401(k) Restricted Stock Units 0 2010-05-24 4 M 0 5000 0 D 2010-05-24 Genzyme common stock (GENZ) 5000 0 D Restricted stock unit shares automatically sold to cover withholding tax obligations. Includes 334 shares purchased from the issuer's Employee Stock Purchase Plan from January 2010 - April 2010. Each restricted stock unit represents a contingent right to receive one share of Genzyme common stock. The restricted stock units vest 100% on the 3rd anniversary of the date of grant. Susan P. Cogswell, Attorney-in-Fact 2010-05-26 -----END PRIVACY-ENHANCED MESSAGE-----